Observational studyBone marrow transplantation2026
Role of consolidative radiotherapy in preventing relapses and subsequent salvage ASCT in early-stage classic Hodgkin lymphoma.
Observational study in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of consolidative radiotherapy (RT) in the upfront management of patients with early-stage classic Hodgkin lymphoma (cHL) is a subject of debate. Particularly, its impact on preventing relapses and the subsequent necessity of salvage autologous stem cell transplantation (ASCT). We analyzed in this multicenter retrospective study data of patients with early-stage cHL. The study evaluates whether the omission of RT increases the risk of relapse and consequently the need for ASCT. Relapse rates and frequency of ASCT were compared between patients who got combined modality treatment (CMT) versus chemotherapy alone. A total of 490 patients (median age 27, mean follow-up 59 months) were included, with 57.8% receiving CMT. Relapse rates in chemotherapy alone and the CMT cohort were 10.6% and 8.5% (p = 0.92), respectively. Frequency of ASCT in chemotherapy alone and CMT arm were 3.9% and 5.3% (p = 0.19), respectively. Post-ASCT complete metabolic remission rate was similar (80% in CMT vs 75% in chemotherapy alone; p = 0.78). Five-year overall survival rate was not different (HR: 1.03; p = 0.95). Our real-world data suggests that omission of routine consolidative RT in patients with early-stage cHL does not increase the risk of relapse or the likelihood of undergoing ASCT.
Indexed as
Identifiers
42209737What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.